Original Research

Factors associated with multi-drug-resistant tuberculosis in Dakar, Senegal, 2010-2016

Mbouna Ndiaye, Pauline K. Yanogo, Bernard Sawadogo, Fadima Diallo, Simon Antara, Nicolas Meda
Journal of Public Health in Africa | Vol 10, No 2 | a910 | DOI: https://doi.org/10.4081/jphia.2019.1099 | © 2024 Mbouna Ndiaye, Pauline K. Yanogo, Bernard Sawadogo, Fadima Diallo, Simon Antara, Nicolas Meda | This work is licensed under CC Attribution 4.0
Submitted: 15 November 2024 | Published: 31 December 2019

About the author(s)

Mbouna Ndiaye, West Africa Field Epidemiology Training Program (WAFETP), Burkina Faso
Pauline K. Yanogo, West Africa Field Epidemiology Training Program (WAFETP), Burkina Faso; and, Faculty of Medicine, University Ouaga, Burkina Faso
Bernard Sawadogo, West Africa Field Epidemiology Training Programme (WAFETP), Burkina Faso
Fadima Diallo, West Africa Field Epidemiology Training Programme (WAFETP), Burkina Faso
Simon Antara, West Africa Field Epidemiology Training Programme (WAFETP), Burkina Faso
Nicolas Meda, West Africa Field Epidemiology Training Program (WAFETP), Burkina Faso; and, Faculty of Medicine, University Ouaga, Burkina Faso

Full Text:

PDF (364KB)

Abstract

According to the World Health Organization, multidrug-resistant tuberculosis (MDR-TB) represents a major obstacle towards successful TB treatment and control. In Dakar, MDR-TB management began in 2010 with the strengthening of diagnostic resources. The objective of this study was to identify the factors associated with multidrug-resistant tuberculosis in Dakar between 2010 and 2016. We conducted a case-control study from January 10 to February 28, 2017 in tuberculosis centers in Dakar. of 169 cases and 507 controls. We used logistic regression with Epi-info version 7.2.1. to estimate the odds ratios of association. Factors significantly associated with MDR-TB were: residing in a periurban area (ORa=1.8; 95% CI (1.5-4.9); p=0.024), presence of MDR-TB in the entourage of patient (ORa=7.0; 95% CI (6.1-9.5); p=0.002), previous treatment failure (ORa=29.5; 95% CI (27.3-30.1); p=0.000), treatment not directly observed by a health care provider (ORa=4.3; 95% CI (4.1-7,2); p=0.000) and irregularity of treatment (ORa=1.7; 95% CI (0.5-5.4); p=0.037). Focusing interventions on population at-risk will prevent MDR-TB.

Keywords

multidrug-resistant tuberculosis; factors; Dakar

Metrics

Total abstract views: 1293
Total article views: 434

 

Crossref Citations

1. Risk factors for multidrug-resistant tuberculosis in the Central African Republic: A case-control study
Jean de Dieu Longo, Sylvain Honoré Woromogo, Gaspard Tekpa, Henri Saint-Calvaire Diemer, Hervé Gando, Fernand Armel Djidéré, Gérard Grésenguet
Journal of Infection and Public Health  vol: 16  issue: 9  first page: 1341  year: 2023  
doi: 10.1016/j.jiph.2023.06.007

2. Influence of COVID-19 on the notification of drug-resistant pulmonary tuberculosis cases
Nathalia Halax Orfão, Rubia Laine de Paula Andrade, Antônio Ruffino-Netto, Leila Wiedmann Florentino da Silva, Tereza Cristina Scatena Villa, Marva Lynn Seifert, Adriana Zilly, Marcos Augusto Moraes Arcoverde, Ismael Hoare, Ricardo Izurieta, Reinaldo Antônio da Silva-Sobrinho
BMC Infectious Diseases  vol: 23  issue: 1  year: 2023  
doi: 10.1186/s12879-023-08463-x

3. Opinion review of drug resistant tuberculosis in West Africa: tackling the challenges for effective control
Isaac Darko Otchere, Adwoa Asante-Poku, Kodjo Francis Akpadja, Awa Ba Diallo, Adama Sanou, Prince Asare, Stephen Osei-Wusu, Nneka Onyejepu, Bassirou Diarra, Yaotsè Anoumou Dagnra, Aderemi Kehinde, Martin Antonio, Dorothy Yeboah-Manu
Frontiers in Public Health  vol: 12  year: 2024  
doi: 10.3389/fpubh.2024.1374703